Nature Communications (Oct 2022)
Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer
Abstract
Accumulating evidence suggest that chemotherapy could paradoxically promote cancer metastasis. Here the authors report that, in preclinical breast cancer models, adjuvant treatment with doxorubicin induces the formation of an immunosuppressive metastatic niche that promotes relapse but that can be reverted with pharmacological blockade of complement signaling.